Skip to main content
. 2009 Sep 8;18(2):264–274. doi: 10.1038/mt.2009.205

Figure 4.

Figure 4

Enhanced therapeutic efficacy of combined therapy of Ad-ΔB7/IL-12/4-1BBL and DCs. B16-F10 tumors were grown subcutaneously in the abdomen of C57BL/6 mice and were subsequently injected with PBS (open diamonds), DCs (filled triangles), Ad-ΔB7/IL-12/4-1BBL (filled circles), or Ad-ΔB7/IL-12/4-1BBL plus DCs (filled squares). Virus was injected intratumorally three times (2.5 × 109 VP/time) with 2 days interval. DCs (1 × 106) were also injected itratumorally three times between the virus injections with 2-day interval. Tumor growth was monitored every day after each treatment. (a) Combined treatment group showed markedly enhanced antitumor effect compared with either Ad-ΔB7/IL-12/4-1BBL or DCs alone group (P < 0.01). Ad-ΔB7/IL-12/4-1BBL or DCs alone group also showed antitumor effect (P < 0.01 versus PBS group). (b) Survival percentage of B16-F10 melanoma-bearing mice in different groups. Survival was significantly improved by Ad-ΔB7/IL-12/4-1BBL plus DCs compared with either Ad-ΔB7/IL-12/4-1BBL or DCs alone group (P < 0.01). **P < 0.01. 4-1BBL, 4-1BB ligand; DC, dendritic cell; PBS, phosphate-buffered saline.